Biotalys N.V.
BTLS.BR
Get informed when a big investor buys or sells
+ FollowMarket Cap$80.8M
Close$
$0.11
93.6% downside
Current Fair Value
93.6% downsideOvervalued by 93.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $80.80 Million |
|---|---|
| Enterprise Value | $72.11 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.42 |
| Beta | 1.42 |
| Outstanding Shares | 39,284,000 |
Return
| Return on Equity | -112.03% |
|---|---|
| Return on Assets | -74.20% |
| Return on Invested Capital | -86.15% |
Valuation & Multiples
| P/E Ratio | -4.04 |
|---|---|
| PEG | -32.61 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.84 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$689,500
Average shareholder expectationNext Earnings Call
Expected Date
March 5, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biotalys N.V.
38 employees
CEO: Carlo Boutton Biotalys N.V. is an agricultural technology firm dedicated to innovating and creating advanced biological solutions for safeguarding both food and cultivated crops. Its product pipeline prominently features biofungicides, bioinsecticides...